Radioligand Therapy With <sup>177</sup>Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 30995089.
- Also identified by DOI 10.2214/AJR.18.20845.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<b>OBJECTIVE.</b> Several clinical studies have shown the efficacy of <sup>177</sup>Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) for metastatic castration-resistant prostate cancer (mCRPC). The purpose of this article is to present results of a systematic review and meta-analysis aimed at compiling and outlining efficacy and safety data on <sup>177</sup>Lu-PSMA RLT for mCRPC across all studies published to date. <b>CONCLUSION.</b> The results of the systematic review and meta-analysis suggest that <sup>177</sup>Lu-PSMA RLT is an effective treatment of advanced-stage mCRPC that is refractory to standard therapeutic options and that it has a low toxicity profile. High-level evidence from randomized control trials is crucial for confirming the effectiveness of <sup>177</sup>Lu-PSMA RLT and for instituting this therapy in the routine clinical care of patients with mCRPC.
Medical subject headings
- Lutetium
- Prostate-Specific Antigen
- Prostatic Neoplasms, Castration-Resistant
- Radioisotopes